Home » Topics » BioWorld Science

BioWorld Science
RSS

MOR-106 moves into phase II development for atopic dermatitis with IGUANA trial

May 3, 2018

NeoImmuneTech enters clinical trial collaboration with Roche

May 3, 2018

FDA grants rare pediatric disease designation to CLR-131 for neuroblastoma

May 3, 2018

Millennium Pharmaceuticals initiates first-in-human trial of TAK-164

May 3, 2018

First-in-human study of hepatitis B DNA vaccine JNJ-64300535

May 3, 2018

Enrollment ongoing in phase III trial of enfortumab vedotin for urothelial cancer

May 3, 2018

EMA approves Alpivab for the treatment of influenza

May 3, 2018

YW-1128, a WNT pathway inhibitor, shows promising in vivo results for metabolic disorders

May 3, 2018

Janssen to acquire Benevir Biopharm

May 3, 2018

Merck KGaA and SFJ partner on abituzumab in metastatic colorectal cancer

May 3, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...
AI drug developer Insilico to raise $292 million in Hong Kong IPO
BioWorld
Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to advance its clinical pipeline and invest...